Literature DB >> 11405649

Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward alpha(1)- and alpha(2)-adrenoceptors.

R Barbaro1, L Betti, M Botta, F Corelli, G Giannaccini, L Maccari, F Manetti, G Strappaghetti, S Corsano.   

Abstract

A series of new pyridazin-3(2H)-one derivatives (3 and 4) were evaluated for their in vitro affinity toward both alpha(1)- and alpha(2)-adrenoceptors by radioligand receptor binding assays. All target compounds showed good affinities for the alpha(1)-adrenoceptor, with K(i) values in the low nanomolar range. The polymethylene chain constituting the spacer between the furoylpiperazinyl pyridazinone and the arylpiperazine moiety was shown to influence the affinity and selectivity of these compounds. Particularly, a gradual increase in affinity was observed by lengthening the polymethylene chain up to a maximum of seven carbon atoms. In addition, compound 3k, characterized by a very interesting alpha(1)-AR affinity (1.9 nM), was also shown to be a highly selective alpha(1)-AR antagonist, the affinity ratio for alpha(2)- and alpha(1)-adrenoceptors being 274. To gain insight into the structural features required for alpha(1) antagonist activity, the pyridazinone derivatives were submitted to a pharmacophore generation procedure using the program Catalyst. The resulting pharmacophore model showed high correlation and predictive power. It also rationalized the relationships between structural properties and biological data of, and external to, the pyridazinone class.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11405649     DOI: 10.1021/jm010821u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Variable selection and specification of robust QSAR models from multicollinear data: arylpiperazinyl derivatives with affinity and selectivity for alpha2-adrenoceptors.

Authors:  D W Salt; L Maccari; M Botta; M G Ford
Journal:  J Comput Aided Mol Des       Date:  2004 Jul-Sep       Impact factor: 3.686

2.  Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst.

Authors:  Madhu Chopra; Ruby Gupta; Swati Gupta; Daman Saluja
Journal:  J Mol Model       Date:  2008-07-30       Impact factor: 1.810

3.  An efficient synthesis and reactions of novel indolylpyridazinone derivatives with expected biological activity.

Authors:  Samar A Abubshait
Journal:  Molecules       Date:  2007-01-10       Impact factor: 4.411

4.  A novel structural framework for α(1A/D)-adrenoceptor selective antagonists identified using subtype selective pharmacophores.

Authors:  Emily S Stoddart; Sevvandi Senadheera; Iain J A MacDougall; Renate Griffith; Angela M Finch
Journal:  PLoS One       Date:  2011-05-10       Impact factor: 3.240

5.  Methyl 4-{[6-(4-bromo-phen-yl)-3-oxo-2,3,4,5-tetra-hydro-pyridazin-4-yl]methyl}benzoate.

Authors:  Adailton J Bortoluzzi; Luciana B P Souza; Antônio C Joussef; Emerson Meyer
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-04-29

6.  Potassium Hydroxide Impregnated Alumina (KOH-Alumina) as a Recyclable Catalyst for the Solvent-Free Multicomponent Synthesis of Highly Functionalized Substituted Pyridazines and/or Substituted Pyridazin-3(2H)-ones under Microwave Irradiation.

Authors:  Hormi Mecadon; Bekington Myrboh
Journal:  ISRN Org Chem       Date:  2011-04-12

7.  Identification of two novel α1-AR agonists using a high-throughput screening model.

Authors:  Fang Xu; Hong Chen; Xuelan He; Jingyi Xu; Bingbing Xu; Biyun Huang; Xue Liang; Mu Yuan
Journal:  Molecules       Date:  2014-08-20       Impact factor: 4.411

8.  Approaches towards the synthesis of a novel class of 2-amino-5-arylazonicotinate, pyridazinone and pyrido[2,3-d]pyrimidine derivatives as potent antimicrobial agents.

Authors:  Hamada Mohamed Ibrahim; Haider Behbehani; Mohamed H Elnagdi
Journal:  Chem Cent J       Date:  2013-07-17       Impact factor: 4.215

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.